U.S. Markets close in 3 hrs 31 mins

Wired News – Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinson’s Treatment

Stock Monitor: ProQR Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Axovant most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Terms of the License Deal

  • Oxford BioMedica will be the clinical and commercial supplier of AXO-Lenti-PD.
  • Axovant will fund all clinical development costs and manufacturing process development and scale-up activities for AXO-Lenti-PD.
  • The Company obtained rights to AXO-Lenti-PD as well as its predecessor product ProSavin®, for an initial payment of $30 million in cash, $5 million of which will be applied as a credit against the process development work and clinical supply that Oxford BioMedica will provide to Axovant.
  • Oxford BioMedica is also eligible to receive additional development, regulatory and commercial milestone payments potentially in excess of $812 million, and tiered royalties on net sales of AXO-Lenti-PD, if approved.
  • Roivant will purchase $25 million of Axovant's common shares, which will support the clinical development of AXO-Lenti-PD and additional business development activities.
  • Fraser Wright, PhD, the Co-Founder and former Chief Technology Officer of Spark Therapeutics, will join Axovant as Chief Technology Officer overseeing the Company's gene therapy initiatives.
  • Axovant is likely to initiate a Phase-1/2 dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018.

Axovant's Expertise in Neurological Disorders Makes the Company an Ideal Development and Commercialization Partner for this Programme

John Dawson, CEO of Oxford BioMedica, stated that the Company is delighted to sign this significant agreement which not only underlines its LentiVector® enabled platform and product development strategy but further demonstrates Oxford BioMedica's ability to build multiple partnerships with leaders in their respective therapeutic fields. This agreement also successfully demonstrates Oxford BioMedica's pre-stated strategy to externalize product development beyond the end of the pre-clinical phase.

John added that Axovant's expertise and focus on neurological disorders, which includes Parkinson's disease, makes them an ideal development and commercialization partner for this programme.

Post announcement of the news shares of Axovant surged in pre-market trade.

About Parkinson's Disease

Parkinson's disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Early in the disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking. Thinking and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are also common, occurring in more than a third of people with Parkinson's disease.

About AXO-Lenti-PD

AXO-Lenti-PD, formerly OXB-102, is an investigational gene therapy for Parkinson's disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain and is designed to provide patient benefit for multiple years following a single administration. AXO-Lenti-PD is a next-generation gene therapy with a modified payload configuration of the predecessor product, ProSavin®, to further improve endogenous dopamine production.

About Oxford BioMedica

Oxford BioMedica is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries have built a sector-leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex-vivo products both in-house and with partners. Oxford BioMedica is based across several locations in Oxfordshire, United Kingdom and employs more than 320 people.

About Axovant Sciences Ltd

Founded in 2014 and headquartered in Basel, Switzerland, Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. Axovant is a member of the Roivant family of companies

Stock Performance Snapshot

June 07, 2018 - At Thursday's closing bell, Axovant's stock rose 5.49%, ending the trading session at $4.80.

Volume traded for the day: 86.16 million shares, which was above the 3-month average volume of 2.75 million shares.

Stock performance in the last month – up 321.05%; and previous three-month period – up 201.89%

After yesterday's close, Axovant's market cap was at $455.52 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381